Gene mutations in Indian patients with prostate cancer
Not Applicable
- Conditions
- Health Condition 1: C61- Malignant neoplasm of prostate
- Registration Number
- CTRI/2022/05/042780
- Lead Sponsor
- niversity of Tornto
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients with metastatic prostate cancer
Willing to participate
Exclusion Criteria
Localised prostate cancer
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Prevalence of gremlin mutation in patients with metastatic prostate cancerTimepoint: 4 weeks
- Secondary Outcome Measures
Name Time Method Prevalence of BRCA2 mutation in patients with metastatic prostate cancerTimepoint: 4 weeks